Regeneron Sees Infringement In Rivals' Biosimilar Eye Meds
Regeneron has defended the validity of its U.K. eye medicine patents in a London court amid a feud with a biosimilars specialist and its licensing partner, alleging that their plans to...To view the full article, register now.
Already a subscriber? Click here to view full article